Explore validated immunodeficient mouse models for human immune system reconstitution, tumor xenograft studies, and preclinical therapeutic evaluation.
Reliable Xenograft Model Development
Supports CDX, hematological tumor, orthotopic, and metastatic models for preclinical efficacy and pharmacology studies.
Versatile Humanized Mouse Applications
Suitable for PBMC- and HSC-based human immune system reconstitution across oncology, immunology, and translational research.
Severe Immunodeficiency
Profound depletion of T, B, and NK cells supports efficient engraftment of human cells and tissues.
Overview
Product
FAQs
Overview
Validated Immunodeficient Models for Advanced Preclinical Research
Immunodeficient mice provide controlled in vivo platforms for studying human cells, tissues, tumors, and immune responses with reduced host-mediated rejection. Cyagen offers well-characterized models, including NKG mice with profound T-, B-, and NK-cell deficiency, to support flexible study design, reproducible model establishment, and dependable preclinical data generation across a broad range of biomedical research programs.
Research on hematopoietic regulation,
Pathological research on myeloid leukemia,
Research on the mechanism of atherosclerosis,
Research on the regulation of immune and inflammatory responses,
Research on other hematological tumors.
Investigating the pathogenesis and developing vaccines for arboviruses such as DENV, ZIKV, YFV, and CHIKV;
Studying antiviral immune responses, interferon stimulation, and JAK-STAT signaling.
Investigating the pathogenesis and developing vaccines for arboviruses such as DENV, ZIKV, YFV, and CHIKV;
Studying antiviral immune responses, interferon stimulation, and JAK-STAT signaling.
Oncology: Investigating the mechanisms underlying tumor growth and metastasis, and evaluating the efficacy of antitumor drugs.
Immunology: Exploring the mechanisms of immune cell development and maturation, as well as the pathogenesis of immune diseases.
Epidemiology: Examining the mechanisms of viral and bacterial infectious disease pathogenesis.
Stem Cell Biology: Investigating the potential of human stem cell transplantation.
Oncology: Research of tumor growth and metastasis and screening of anti-tumor drugs;
Immunology: Research on the proliferation of immune cells and the mechanism of immune diseases;
Infectious diseases: Research on the pathogenesis of viral and bacterial infectious diseases;
Stem cell biology: Research on human-derived stem cell transplantation.
Research on immune system defects;
Research on cancer and xenotransplantation, etc.;
Toxicology research.
Items: 1 to 10 of 50
1
2
3
4
5
Previous Page
Next Page
FAQs
Frequently Asked Questions (FAQs)
What is the process for establishing human tumor xenografts in immunodeficient mice?
Establishing a human tumor xenograft follows a standardized workflow:
1. Select the host. Choose a strain based on the tumor type and study goal. Options range from T cell-deficient BALB/c nude mice, often enough for CDX, to severely immunodeficient NKG mice (lacking T, B and functional NK cells), which suit difficult-to-engraft PDX, hematologic tumors and humanized models. 2. Prepare the material. For CDX, expand human cancer cells in culture, harvest them in log-phase growth, and resuspend them in serum-free medium, often mixed with a basement membrane matrix such as Matrigel. For PDX, keep fresh patient tumor tissue in cold preservation medium, cut it into small fragments (about 2–3 mm³), and implant it as soon as possible. 3. Inoculate or implant. Inject cells or implant tissue fragments subcutaneously (usually into the flank) for easy monitoring, or orthotopically (into the organ of origin) to better recreate the native tumor microenvironment and metastatic behavior. Hematologic tumors are usually injected intravenously. 4. Monitor and passage. Track tumor growth with calipers or non-invasive imaging such as bioluminescence. Once tumors reach a defined size, passage PDX tumors into new mice and cryopreserve them to build a stable model bank. 5. Validate. Confirm that the xenograft keeps the features of the original tumor with histopathology (H&E and immunohistochemistry) and STR or genomic profiling. Rule out mouse-cell overgrowth and EBV-associated human lymphoma before using the model in efficacy studies.
Why are immunodeficient mice required for establishing human tumor xenograft models?
Immunodeficient mice are needed because of immune rejection. A mouse with an intact immune system recognizes human cells as foreign, and its T cells, supported by B cells, antibodies, NK cells, macrophages and complement, reject the human graft within days to weeks. Strains such as BALB/c nude, NOD-SCID and NKG mice lack some or all of these immune barriers, so human tumor cells can survive, become vascularized by the host, and grow as solid tumors. Researchers can then study the behavior of real human cancers in a living system and test human-specific anti-cancer therapies in vivo before clinical development.
What is the primary difference between immunocompetent and immunodeficient mice?
The difference lies in the functional status of their immune systems:
Immunocompetent Mice: These mice have a full, functional immune system (including T, B, and NK cells). Common strains include C57BL/6 and BALB/c. They are used to study normal immune responses.
Immunodeficient Mice: These mice have specific genetic mutations that "shut down" parts of their immune system. Strains like BALB/c Nude (lacks T cells) or NKG (lacks T, B, and NK cells) allow for the growth of foreign tissues, such as human tumors, without rejection.
When should I use immunocompetent mice for my research?
Immunocompetent models are ideal for studies where a host immune response is required. Key applications include:
Syngeneic Tumor Models: Infiltrating mouse-derived tumor cell lines into mice of the same genetic background.
Immune Checkpoint Inhibitor Testing: Evaluating therapies like anti-PD-1 or anti-CTLA-4.
Vaccine Development: Testing the efficacy of vaccines in triggering an immune memory.
Autoimmune Diseases: Studying conditions like rheumatoid arthritis or lupus.
How has the development of immunodeficient mice evolved over the years?
Nude mice (1960s). The story began with the discovery of the athymic nude mouse in 1962. A Foxn1 mutation leaves these mice without a thymus and mature T cells, and in 1969 they hosted the first human tumor xenograft. But they keep functional B cells and highly active NK cells, which limits the human tissues they can accept. SCID mice (1983). A mutation in the Prkdc gene blocks both T and B cell development. However, many SCID mice become “leaky” as they age, producing some functional T and B cells, and their NK activity stays high. NOD-SCID mice (1990s). Moving the scid mutation onto the NOD background added the NOD strain’s innate immune defects, including reduced NK cell, macrophage and complement function, and greatly reduced leakiness. Residual NK activity and a short lifespan caused by thymic lymphomas remained limitations. Il2rg-null mice (2000s). The major breakthrough came from knocking out the IL-2 receptor common gamma chain gene (Il2rg) on the NOD-scid background, first in the NOG (2002) and NSG (2005) strains. This removed functional NK cells. Cyagen's NKG mouse (NOD.Cg-Prkdc^scid Il2rg^em1Cya/Cya) belongs to this generation: it lacks mature T cells, B cells and functional NK cells and is one of the most permissive hosts for human cell and tissue engraftment. Next-generation strains. Newer strains build on this platform. Some express human cytokines, some lack mouse MHC molecules, and some carry Kit mutations, so they better support human immune and hematopoietic cells.
What were the key technical improvements in the latest generation of immunodeficient mice?
Loss of functional NK cells. Knocking out Il2rg (γc/CD132) blocks IL-2, IL-4, IL-7, IL-9, IL-15 and IL-21 signaling, which prevents NK cell development. This is the main reason human cell engraftment is so efficient.
Reduced innate rejection. The NOD background carries a SIRPα variant that binds human CD47 and lowers macrophage phagocytosis of human cells, along with a complement C5 deficiency.
Stability. Leakiness is minimal, so mice rarely develop functional mouse T or B cells as they age.
Longevity. Unlike NOD-SCID mice, Il2rg-null strains rarely develop thymic lymphomas and live much longer, which supports long-term studies such as humanized immune system models.
Support for humanization. Derivative strains engineered to express human cytokines (e.g., IL-3, GM-CSF, SCF, IL-15) or to lack mouse MHC molecules better support specific human immune cell lineages and reduce GvHD.
What is a Humanized Immune System (HIS) mouse model?
An HIS mouse is a highly immunodeficient mouse that has been "reconstituted" with a functional human immune system. This is typically achieved by transplanting:
Human PBMCs: For short-term studies focusing on mature T-cell responses.
Human Hematopoietic Stem Cells (HSCs): For long-term studies where a full range of human immune cells (T, B, NK, myeloid cells) develops within the mouse’s bone marrow.
These models allow researchers to study the interaction between the human immune system and human tumors in an in vivo setting.
What support does Cyagen provide for the development of customized HIS models?
Cyagen offers a comprehensive platform ranging from our proprietary NKG host strains to fully validated HSC-Humanized and PBMC-Humanized models. Furthermore, we provide customized gene-editing services to create niche models that express specific human cytokines or MHC molecules, tailored to your specific drug target requirements.
What are the primary characteristics and applications of SCID mice?
SCID (Severe Combined Immunodeficient) mice carry a mutation in the Prkdc gene, which results in a near-complete deficiency of functional T and B lymphocytes.
Key Applications: 1. Tumor Xenografts (CDX): Widely used as hosts for the transplantation of human tumor cell lines to evaluate preclinical drug efficacy. 2. Humanization: Serving as a platform for reconstituting the human immune system. 3. Immunology Research: Studying the basic functions of the innate immune system (e.g., NK cells) in the absence of adaptive immunity.
Are BALB/c mice considered immunodeficient models?
No. Standard BALB/c mice are immunocompetent, with a complete and functional immune system that includes T cells, B cells and natural killer (NK) cells. The confusion comes from the fact that several popular immunodeficient models are built on the BALB/c background:
BALB/c (wild-type). An immunocompetent inbred strain widely used in immunology, antibody production, vaccine research and syngeneic tumor models. Its immune response naturally leans toward a Th2 type. BALB/c nude (Foxn1^nu). An immunodeficient variant. A Foxn1 mutation leaves these mice without a thymus, so they have very few mature T cells. They are also hairless, their most recognizable feature. C.B-17-scid. A BALB/c-congenic strain carrying the scid mutation, lacking both T and B cells.
Understanding the Athymic Nude Model. Could you define what characterizes a "Nude Mouse" in a laboratory setting?
A nude mouse is a specialized laboratory strain (most commonly the BALB/c Nude) characterized by a genetic mutation in the Foxn1 gene. This mutation results in two distinct phenotypes:
Athymia: The mouse is born without a thymus, meaning it cannot produce mature T-lymphocytes. This makes the mouse severely immunodeficient.
Alopecia: The mutation also affects the hair follicles, leaving the mouse nearly hairless or "nude."
Because they lack an adaptive T-cell response, they will not reject "foreign" tissues, such as human cancer cells or skin grafts, making them a "permissive" host for cross-species studies.
Contact Us
Connect with our experts for your custom animal model needs. Please fill out the form below to start a conversation or request a quote.
Cyagen values your privacy. We’d like to keep you informed about our latest offerings and insights. Your preferences:
You may unsubscribe from these communications at any time. See our Privacy Policy for details on opting out and data protection.
By clicking the button below, you consent to allow Cyagen to store and process the personal information submitted in this form to provide you the content requested.
Stay Updated with the Latest from Cyagen
Get the latest news on our research models, CRO services, scientific resources, and special offers—tailored to your research needs and delivered straight to your inbox.